Company
flowbone SA
Incorporated
July 2020
Headquarter
Lausanne
Support
Restoring hip strength to resist breaking
FLOWBONE is involved in the development and promotion of a revolutionary biomaterial for the minimal-invasive augmentation of fragile bones. FLOWBONE, follows a completely new treatment approach allowing fragilized bone to augment and repair itself without impeding bone mechanics or blood flow within the bone. The product can be used for both bone repair and fragility fracture prevention, and their initial focus will be targeting high risk areas such as the spine and hips. The technology is the result of 6+ years of research at EPFL is currently in the pre-clinical phase preparing for clinical trials prior to market commercialization.
